Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

February 29, 2020

Conditions
Allergic Rhinitis
Interventions
DRUG

Placebo

Patients will be treated by placebo

DRUG

Fluticasone propionate

Patients will receive fluticasone nasal spray

DRUG

Fluticasone/Azelastine nasal spray

Patients will receive Dymista nasal spray

PROCEDURE

Nasal Allergen Challenge

All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration

Trial Locations (1)

60637

The University of Chicago Medicine, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT02402465 - Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter